Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.77 |
| ▸ | MME | P08473 | 2/20 | 0.76 |
| ▸ | BCL2L2 | Q92843 | 6/20 | 0.73 |
| ▸ | BCL2 | P10415 | 5/20 | 0.73 |
| ▸ | BAD | Q92934 | 5/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.73 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | CRHBP | P24387 | 1/20 | 0.69 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25198529 | 1.00 | MAPT (0.77) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25200467 | 0.94 | MME (0.73) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25265299 | 0.94 | MAPT (0.82) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25198109 | 0.94 | BCL2L2 (0.82) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25185087 | 0.94 | MME (0.73) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25188655 | 0.94 | MAPT (0.82) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25265304 | 0.94 | BCL2L2 (0.82) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25185088 | 0.94 | MME (0.73) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL25265368 | 0.94 | MME (0.73) | MAPTMMEBCL2L2BCL2BAD | |
| SCHEMBL28520077 | 0.92 | BCL2L2 (0.73) | MAPTMMEBCL2L2BCL2BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885MME 322/4885BCL2L2 992/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885MME 131/4885BCL2L2 1431/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885MME 131/4885BCL2L2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.